Preli Pharmaceutical's Carfilzomib for Injection (60mg) Approved for Listing in China

MetaMuskRat · 2026-03-17T08:39:08+00:00

People Finance News, March 17 — Prili Pharmaceutical recently received a drug registration approval certificate from the National Medical Products Administration (NMPA) for Carfilzomib for Injection (60mg) (registration category: chemical drug category 4). The product is deemed to have passed generic drug quality and efficacy consistency evaluation and has officially received market approval. This product is a potent anti-tumor drug for treating relapsed/refractory multiple myeloma.

MetaMuskRat

2026-03-17 08:39:08

People’s Financial News, March 17 — Puli Pharmaceutical recently received the drug registration approval from the National Medical Products Administration (NMPA) for Carfilzomib for Injection (60mg) (registration category: Chemical Drugs, Class 4). This approval is considered to meet the consistency evaluation for generic drug quality and efficacy, officially allowing the product to be marketed. This medication is a potent anti-tumor drug used to treat relapsed/refractory multiple myeloma.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.